Table 1.
Baseline clinical characteristics of the study cohort.
| All (n=563) | HF (n=51) | Non-HF (n=512) | P Value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 62±14 | 62±14 | 62±14 | 0.96 |
| Age>60y, n(%) | 350 (64.8) | 30 (58.8) | 320 (62.5) | 0.65 |
| Male sex, n(%) | 298 (52.9) | 24 (47.1) | 274 (53.5) | 0.38 |
| BMI, kg/m2 | 28.2±6.6 | 26.8±5.4 | 28.3±6.7 | 0.07 |
| Duration of follow-up,d,[Q1,Q3] | 445,[148,1066] | 448,[239,1019] | 442,[144,1068] | 0.24 |
| Cardiovascular risks and disease history | ||||
| Hypercholesterolemia, n(%) | 139 (24.7) | 20 (39.2) | 119 (23.2) | 0.01 |
| Hypertension, n(%) | 169 (30.0) | 23 (45.1) | 146 (28.5) | 0.01 |
| Diabetes, n(%) | 58 (10.3) | 6 (11.8) | 52 (10.2) | 0.43 |
| Obesity, n(%) | 160 (28.4) | 13 (25.5) | 147 (28.7) | 0.75 |
| Current/previous | 215 (38.2) | 23 (451.) | 192 (37.5) | 0.53 |
| smoker,n(%) | ||||
| ≥2 CV risk factors*, n(%) | 148 (26.3) | 19 (37.3) | 129 (25.2) | 0.07 |
| Coronary heart disease, n(%) | 66 (11.7) | 10 (19.6) | 56 (10.4) | 0.06 |
| Atrial fibrillation/flutter, n(%) | 37 (6.6) | 2 (3.9) | 35 (6.8) | 0.33 |
| Peripheral artery disease, n(%) | 32 (5.7) | 3 (5.9) | 29 (5.7) | 0.57 |
| All | HF | Non-HF | P | |
| Chronic kidney disease, n(%) | 18 (3.2) | 2 (3.9) | 16 (3.1) | 0.50 |
| Cerebrovascular disease, n(%) | 36 (6.4) | 4 (7.8) | 32 (6.3) | 0.42 |
| DVT/pulmonary embolism, n(%) | 29 (5.2) | 1 (2.0) | 28 (5.5) | 0.24 |
| Pre-existing CV diseases#, n (%) | 130 (23.1) | 14 (27.5) | 116 (22.7) | 0.27 |
| Cardiovascular medicine | ||||
| Beta-blockers, n(%) | 60 (10.7) | 12 (23.5) | 48 (9.4) | <0.01 |
| ACEI, n(%) | 60 (10.7) | 7 (13.7) | 53 (10.4) | 0.29 |
| ARBs, n(%) | 53 (9.4) | 4 (7.8) | 49 (9.6) | 0.46 |
| Aspirin, n(%) | 138 (24.5) | 11 (21.6) | 127 (24.8) | 0.38 |
| Anticoagulants, n(%) | 53 (9.4) | 2 (3.9) | 51 (10.0) | 0.12 |
| Statins, n(%) | 132 (23.4) | 13 (25.5) | 119 (23.2) | 0.42 |
| Cancer related treatment | ||||
| Anthracycline, n(%) | 481 (85.4) | 47 (92.2) | 434 (84.8) | 0.11 |
| Anthracycline dose, mg/m2, [Q1,Q3] | 180,[177,300] | 255,[180,330] | 180,[173,300] | 0.20 |
| Anthracycline dose >250mg/m2, n(%) | 164 (29.1) | 19 (37.3) | 145 (28.3) | 0.06 |
BMI: body mass index; CV: cardiovascular; DVT: deep venous thrombosis; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker;
*:
CV risk factors include obesity, hypertension, hypercholesterolemia and diabetes;
#:
CV diseases include coronary artery disease, atrial fibrillation/flutter, cerebrovascular disease, and peripheral artery disease; P value: compared between patients with and with no HF.